Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGK1 | O00141 | 4/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 7/20 | 0.39 |
| ▸ | VEGFA | P15692 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29780203 | 1.00 | SGK1 (0.41) | SGK1EPAS1VEGFAPTGS1PTGS2 | |
| SCHEMBL23461602 | 0.83 | EPAS1 (0.42) | EPAS1VEGFAPTGS1PTGS2 | |
| SCHEMBL29780196 | 0.83 | EPAS1 (0.42) | EPAS1VEGFAPTGS1PTGS2 | |
| SCHEMBL29780217 | 0.82 | EPAS1 (0.39) | SGK1EPAS1VEGFAPTGS1PTGS2 | |
| SCHEMBL23478125 | 0.82 | EPAS1 (0.39) | SGK1EPAS1VEGFAPTGS1PTGS2 | |
| SCHEMBL23478762 | 0.79 | EPAS1 (0.41) | EPAS1VEGFA | |
| SCHEMBL29780231 | 0.79 | EPAS1 (0.41) | EPAS1VEGFA | |
| SCHEMBL23461085 | 0.78 | EPAS1 (0.56) | EPAS1VEGFA | |
| SCHEMBL29780240 | 0.78 | EPAS1 (0.56) | EPAS1VEGFA | |
| SCHEMBL23461084 | 0.71 | EPAS1 (0.49) | EPAS1VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230024438-A1 | INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| EP-4069212-A1 | INHIBITORS OF HIF-2ALPHA | Arcus Biosciences, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| CN-114760994-A | Inhibitors of HIF-2 alpha | 艾库斯生物科学有限公司 | 2022-07-15 | — | — | CN | disclosed |
| WO-2021113436-A1 | INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021113436-A1 | INHIBITORS OF HIF-2ALPHA | ARCUS BIOSCIENCES, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024438-A1 | INHIBITORS OF HIF-2ALPHA | HIF1AN, HIF1A, EGLN2 | SGK1 2736/4885EPAS1 9/4885VEGFA 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.